{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T10:24:10Z","timestamp":1777026250370,"version":"3.51.4"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,7,22]],"date-time":"2022-07-22T00:00:00Z","timestamp":1658448000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,7,22]],"date-time":"2022-07-22T00:00:00Z","timestamp":1658448000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"AMIDEX","award":["A*MIDEX (BARLEID)"],"award-info":[{"award-number":["A*MIDEX (BARLEID)"]}]},{"DOI":"10.13039\/100013226","name":"Les Laboratories Pierre Fabre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013226","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1007\/s00280-022-04455-x","type":"journal-article","created":{"date-parts":[[2022,7,22]],"date-time":"2022-07-22T12:04:00Z","timestamp":1658491440000},"page":"149-160","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Revisiting metronomic vinorelbine with mathematical modelling: a Phase I trial in lung cancer"],"prefix":"10.1007","volume":"90","author":[{"given":"Fabrice","family":"Barlesi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laure","family":"Deyme","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diane-Charlotte","family":"Imbs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elissa","family":"Cousin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathieu","family":"Barbolosi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvanie","family":"Bonnet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascale","family":"Tomasini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Greillier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa","family":"Galloux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albane","family":"Testot-Ferry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annick","family":"Pelletier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6786-4968","authenticated-orcid":false,"given":"Nicolas","family":"Andr\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Ciccolini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominique","family":"Barbolosi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,7,22]]},"reference":[{"key":"4455_CR1","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/nrclinonc.2014.89","volume":"11","author":"N Andr\u00e9","year":"2014","unstructured":"Andr\u00e9 N, Carr\u00e9 M, Pasquier E (2014) Metronomics: towards personalized chemotherapy? Nat Rev Clin Oncol 11:413\u2013431","journal-title":"Nat Rev Clin Oncol"},{"key":"4455_CR2","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1038\/nrclinonc.2015.204","volume":"13","author":"D Barbolosi","year":"2016","unstructured":"Barbolosi D, Ciccolini J, Lacarelle B, Barlesi F, Andr\u00e9 N (2016) Computational oncology\u2013mathematical modelling of drug regimens for precision medicine. Nat Rev Clin Oncol 13:242\u2013254","journal-title":"Nat Rev Clin Oncol"},{"key":"4455_CR3","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s00280-014-2546-1","volume":"74","author":"D Barbolosi","year":"2014","unstructured":"Barbolosi D, Ciccolini J, Meille C, Elharrar X, Faivre C, Lacarelle B, Andr\u00e9 N, Barlesi F (2014) Metronomics chemotherapy: time for computational decision support. Cancer Chemother Pharmacol 74:647\u2013652","journal-title":"Cancer Chemother Pharmacol"},{"key":"4455_CR4","doi-asserted-by":"publisher","first-page":"6454","DOI":"10.1158\/1078-0432.CCR-09-0970","volume":"15","author":"E Briasoulis","year":"2009","unstructured":"Briasoulis E, Pappas P, Puozzo C, Tolis C, Fountzilas G, Dafni U, Marselos M, Pavlidis N (2009) Dose-ranging study of metronomic oral vinorelbine in patients with advanced refractory cancer. Clin Cancer Res 15:6454\u20136461","journal-title":"Clin Cancer Res"},{"key":"4455_CR5","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1007\/s00280-011-1580-5","volume":"68","author":"L Rajdev","year":"2011","unstructured":"Rajdev L, Negassa A, Dai Q, Goldberg G, Miller K, Sparano JA (2011) Phase I trial of metronomic oral vinorelbine in patients with advanced cancer. Cancer Chemother Pharmacol 68:1119\u20131124","journal-title":"Cancer Chemother Pharmacol"},{"key":"4455_CR6","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1186\/1471-2407-13-263","volume":"13","author":"E Briasoulis","year":"2013","unstructured":"Briasoulis E, Aravantinos G, Kouvatseas G, Pappas P, Biziota E, Sainis I, Makatsoris T, Varthalitis I, Xanthakis I, Vassias A, Klouvas G, Boukovinas I, Fountzilas G, Syrigos KN, Kalofonos H, Samantas E (2013) Dose selection trial of metronomic oral vinorelbine monotherapy in patients with metastatic cancer: a hellenic cooperative oncology group clinical translational study. BMC Cancer 13:263","journal-title":"BMC Cancer"},{"key":"4455_CR7","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1179\/1973947812Y.0000000050","volume":"25","author":"E Kontopodis","year":"2013","unstructured":"Kontopodis E, Hatzidaki D, Varthalitis I, Kentepozidis N, Giassas S, Pantazopoulos N, Vardakis N, Rovithi M, Georgoulias V, Agelaki S (2013) A phase II study of metronomic oral vinorelbine administered in the second line and beyond in non-small cell lung cancer (NSCLC): a phase II study of the Hellenic Oncology Research Group. J Chemother 25:49\u201355","journal-title":"J Chemother"},{"key":"4455_CR8","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1007\/s00280-005-1025-0","volume":"56","author":"RM Lush","year":"2005","unstructured":"Lush RM, McCune JS, Tetteh L, Thompson JA, Mahany JJ, Garland L, Suttle AB, Sullivan DM (2005) The absolute bioavailability of oral vinorelbine in patients with solid tumors. Cancer Chemother Pharmacol 56:578\u2013584","journal-title":"Cancer Chemother Pharmacol"},{"key":"4455_CR9","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.semcancer.2015.09.002","volume":"35","author":"S Benzekry","year":"2015","unstructured":"Benzekry S, Pasquier E, Barbolosi D, Lacarelle B, Barlesi F, Andr\u00e9 N, Ciccolini J (2015) Metronomic reloaded: theoretical models bringing chemotherapy into the era of precision medicine. Semin Cancer Biol 35:53\u201361","journal-title":"Semin Cancer Biol"},{"key":"4455_CR10","doi-asserted-by":"crossref","unstructured":"Faivre C, Barbolosi D, Pasquier E, Andr\u00e9 N (2013) A mathematical model for the administration of temozolomide: comparative analysis of conventional and metronomic chemotherapy regimens. Cancer Chemother Pharmacol 71(3):1013\u20139","DOI":"10.1007\/s00280-013-2095-z"},{"key":"4455_CR11","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1186\/s12885-016-2308-z","volume":"16","author":"X Elharrar","year":"2016","unstructured":"Elharrar X, Barbolosi D, Ciccolini J, Meille C, Faivre C, Lacarelle B, Andr\u00e9 N, Barlesi F (2016) A phase Ia\/Ib clinical trial of metronomic chemotherapy based on a mathematical model of oral vinorelbine in metastatic non-small cell lung cancer and malignant pleural mesothelioma: rationale and study protocol. BMC Cancer 16:278","journal-title":"BMC Cancer"},{"issue":"29","key":"4455_CR12","doi-asserted-by":"publisher","first-page":"47161","DOI":"10.18632\/oncotarget.17562","volume":"8","author":"F Barlesi","year":"2017","unstructured":"Barlesi F, Imbs DC, Tomasini P, Greillier L, Galloux M, Testot-Ferry A, Garcia M, Elharrar X, Pelletier A, Andr\u00e9 N, Mascaux C, Lacarelle B, Cheikh RE, Serre R, Ciccolini J, Barbolosi D (2017) Mathematical modeling for Phase I cancer trials: a study of metronomic vinorelbine for advanced non-small cell lung cancer (NSCLC) and mesothelioma patients. Oncotarget 8(29):47161\u201347166","journal-title":"Oncotarget"},{"key":"4455_CR13","doi-asserted-by":"publisher","first-page":"4713","DOI":"10.1200\/JCO.2002.02.140","volume":"20","author":"LE Friberg","year":"2002","unstructured":"Friberg LE, Henningsson A, Maas H, Nguyen L, Karlsson MO (2002) Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. J Clin Oncol 20:4713\u20134721","journal-title":"J Clin Oncol"},{"key":"4455_CR14","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1098\/rstl.1825.0026","volume":"115","author":"B Gompertz","year":"1825","unstructured":"Gompertz B (1825) On the nature of the function expressive of the law of human mortality and on a new model of determining life contingencies. Phil Trans R Soc 115:513\u2013585","journal-title":"Phil Trans R Soc"},{"key":"4455_CR15","first-page":"6938","volume":"62","author":"G Bocci","year":"2002","unstructured":"Bocci G, Nicolaou KC, Kerbel RS (2002) Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res 62:6938\u20136943","journal-title":"Cancer Res"},{"key":"4455_CR16","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1056\/NEJM197108122850711","volume":"285","author":"J Folkman","year":"1971","unstructured":"Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285:1182\u20131186","journal-title":"N Engl J Med"},{"key":"4455_CR17","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s00228-002-0506-x","volume":"58","author":"P Variol","year":"2002","unstructured":"Variol P, Nguyen L, Tranchand B, Puozzo C (2002) A simultaneous oral\/intravenous population pharmacokinetic model for vinorelbine. Eur J Clin Pharmacol 58:467\u2013476","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"4455_CR18","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1007\/s00280-010-1415-9","volume":"67","author":"AG Pallis","year":"2011","unstructured":"Pallis AG, Chandrinos V, Pavlakou G, Xenidis N, Varthalitis I, Vardakis N, Vamvakas L, Kontopodis E, Rovithi M, Georgoulias V (2011) A multicenter phase I trial of metronomic oral vinorelbine plus cisplatin in patients with NSCLC. Cancer Chemother Pharmacol 67(6):1239\u20131245","journal-title":"Cancer Chemother Pharmacol"},{"key":"4455_CR19","doi-asserted-by":"publisher","first-page":"76979","DOI":"10.1155\/2014\/769790","volume":"2014","author":"ME Cazzaniga","year":"2014","unstructured":"Cazzaniga ME, Torri V, Villa F, Giuntini N, Riva F, Zeppellini A, Cortinovis D, Bidoli P (2014) Efficacy and safety of the all-oral schedule of metronomic vinorelbine and capecitabine in locally advanced or metastatic breast cancer patients: the phase I-II VICTOR-1 study. Int J Breast Cancer 2014:76979","journal-title":"Int J Breast Cancer"},{"issue":"4","key":"4455_CR20","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s00280-012-1945-4","volume":"70","author":"R Addeo","year":"2012","unstructured":"Addeo R, Sperlongano P, Montella L, Vincenzi B, Carraturo M, Iodice P, Russo P, Parlato C, Salzano A, Cennamo G, Lombardi A, Sperlongano R, Prete SD, Caraglia M (2012) Protracted low dose of oral vinorelbine and temozolomide with whole-brain radiotherapy in the treatment for breast cancer patients with brain metastases. Cancer Chemother Pharmacol 70(4):603\u2013609","journal-title":"Cancer Chemother Pharmacol"},{"issue":"10","key":"4455_CR21","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.2147\/OTT.S122106","volume":"21","author":"S Guetz","year":"2017","unstructured":"Guetz S, Tufman A, von Pawel J, Rittmeyer A, Borgmeier A, Ferr\u00e9 P, Edlich B, Huber RM (2017) Metronomic treatment of advanced non-small-cell lung cancer with daily oral vinorelbine\u2014a Phase I trial. Onco Targets Ther 21(10):1081\u20131089","journal-title":"Onco Targets Ther"},{"key":"4455_CR22","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1038\/nrclinonc.2016.64","volume":"13","author":"G Bocci","year":"2016","unstructured":"Bocci G, Kerbel RS (2016) Pharmacokinetics of metronomic chemotherapy: a neglected but crucial aspect. Nat Rev Clin Oncol 13:659\u2013673","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"4455_CR23","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1007\/s12094-018-1989-y","volume":"21","author":"A Camerini","year":"2019","unstructured":"Camerini A, Banna GL, Cinieri S, Pezzuto A, Mencoboni M, Rosetti F, Figueiredo A, Rizzo P, Ricci A, Langenhoven L, Santo A, Addeo A, Amoroso D, Barata F (2019) Metronomic oral vinorelbine for the treatment of advanced non-small cell lung cancer: a multicenter international retrospective analysis. Clin Transl Oncol 21(6):790\u2013795","journal-title":"Clin Transl Oncol"},{"issue":"5","key":"4455_CR24","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1007\/s10637-018-0631-8","volume":"36","author":"F Pasini","year":"2018","unstructured":"Pasini F, Barile C, Caruso D, Modena Y, Fraccon AP, Bertolaso L, Menon D, La Russa F, Crepaldi G, Bononi A, Spezzano R, Padrini R, Corona G, Gusella M (2018) Oral Metronomic Vinorelbine (OMV) in elderly or pretreated patients with advanced non small cell lung cancer: outcome and pharmacokinetics in the real world. Invest New Drugs 36(5):927\u2013932","journal-title":"Invest New Drugs"},{"issue":"8","key":"4455_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0220988","volume":"14","author":"JL Pujol","year":"2019","unstructured":"Pujol JL, Coffy A, Camerini A, Kotsakis A, Mencoboni M, Gusella M, Pasini F, Pezzuto A, Banna GL, Bilir C, Samantas E, Barlesi F, Roch B, Guillou A, Daur\u00e8s JP (2019) An individual patient-data meta-analysis of metronomic oral vinorelbine in metastatic non-small cell lung cancer. PLoS ONE 14(8):e0220988","journal-title":"PLoS ONE"},{"issue":"9","key":"4455_CR26","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1007\/s10147-020-01707-9","volume":"25","author":"K Xu","year":"2020","unstructured":"Xu K, Liu T, Zhang J, Zhou Y, Yang F, Ren T (2020) The efficacy and toxicity of metronomic oral vinorelbine monotherapy in patients with non-small cell lung cancer: a meta-analysis. Int J Clin Oncol 25(9):1624\u20131634","journal-title":"Int J Clin Oncol"},{"issue":"2018","key":"4455_CR27","first-page":"6278403","volume":"27","author":"M D'Ascanio","year":"2018","unstructured":"D\u2019Ascanio M, Pezzuto A, Fiorentino C, Sposato B, Bruno P, Grieco A, Mancini R, Ricci A (2018) Metronomic chemotherapy with vinorelbine produces clinical benefit and low toxicity in frail elderly patients affected by advanced non-small cell lung cancer. Biomed Res Int 27(2018):6278403","journal-title":"Biomed Res Int"},{"issue":"3","key":"4455_CR28","doi-asserted-by":"publisher","first-page":"e199","DOI":"10.3747\/co.24.3486","volume":"24","author":"C Bilir","year":"2017","unstructured":"Bilir C, Durak S, K\u0131z\u0131lkaya B, Hac\u0131bekiroglu I, Nay\u0131r E, Engin H (2017) Efficacy of metronomic vinorelbine in elderly patients with advanced non-small-cell lung cancer and poor performance status. Curr Oncol 24(3):e199\u2013e204","journal-title":"Curr Oncol"},{"key":"4455_CR29","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1186\/s12885-015-1354-2","volume":"15","author":"A Camerini","year":"2015","unstructured":"Camerini A, Puccetti C, Donati S, Valsuani C, Petrella MC, Tartarelli G, Puccinelli P, Amoroso D (2015) Metronomic oral vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer: results of a phase II trial (MOVE trial). BMC Cancer 15:359","journal-title":"BMC Cancer"},{"issue":"3","key":"4455_CR30","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s00280-018-3751-0","volume":"83","author":"M Gusella","year":"2019","unstructured":"Gusella M, Pasini F, Caruso D, Barile C, Modena Y, Fraccon AP, Bertolaso L, Menon D, Crepaldi G, Bononi A, Spezzano R, Telatin GA, Corona G, Padrini R (2019) Clinical outcomes of oral metronomic vinorelbine in advanced non-small cell lung cancer: correlations with pharmacokinetics and MDR1 polymorphisms. Cancer Chemother Pharmacol 83(3):493\u2013500","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6","key":"4455_CR31","doi-asserted-by":"publisher","first-page":"3689","DOI":"10.21873\/anticanres.12647","volume":"38","author":"GL Banna","year":"2018","unstructured":"Banna GL, Camerini A, Bronte G, Anile G, Addeo A, Rundo F, Zangh\u00ec G, Lal R, Libra M (2018) Oral metronomic vinorelbine in advanced non-small cell lung cancer patients unfit for chemotherapy. Anticancer Res 38(6):3689\u20133697","journal-title":"Anticancer Res"},{"issue":"6","key":"4455_CR32","first-page":"3189","volume":"37","author":"M Mencoboni","year":"2017","unstructured":"Mencoboni M, Filiberti RA, Taveggia P, Del Corso L, Del Conte A, Covesnon MG, Puccetti C, Donati S, Auriati L, Amoroso D, Camerini A (2017) Safety of first-line chemotherapy with metronomic single-agent oral vinorelbine in elderly patients with NSCLC. Anticancer Res 37(6):3189\u20133194","journal-title":"Anticancer Res"},{"issue":"5","key":"4455_CR33","doi-asserted-by":"publisher","first-page":"2687","DOI":"10.21873\/invivo.12088","volume":"34","author":"D Rossi","year":"2020","unstructured":"Rossi D, Lippe P, Rocchi MBL, Sarti D, Catalano V, Graziano F, Giordani P, Baldelli A, Fedeli SL, Imperatori L, Laici G, Cappelletti C, Tamburrano T, Bracci R, Alessandroni P (2020) Metronomic oral vinorelbine: an alternative schedule in elderly and patients ps2 with local\/advanced and metastatic NSCLC not oncogene-addicted. In Vivo 34(5):2687\u20132691","journal-title":"In Vivo"},{"issue":"2","key":"4455_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100051","volume":"6","author":"A Camerini","year":"2021","unstructured":"Camerini A, Morabito A, Montanino A, Bernab\u00e9 R, Grossi F, Ramlau R, Ciuleanu TE, Ceresoli GL, Pasello G, de Marinis F, Bosch-Barrera J, Laundreau P, Gautier S (2021) Ta Thanh Minh C, Kowalski D Metronomic oral vinorelbine in previously untreated advanced non-small-cell lung cancer patients unfit for platinum-based chemotherapy: results of the randomized phase II Tempo lung trial. ESMO Open 6(2):100051","journal-title":"ESMO Open"},{"issue":"11","key":"4455_CR35","doi-asserted-by":"publisher","first-page":"955","DOI":"10.2147\/OTT.S153290","volume":"23","author":"DB Sacdalan","year":"2018","unstructured":"Sacdalan DB, Lucero JA, Sacdalan DL (2018) Prognostic utility of baseline neutrophil-to-lymphocyte ratio in patients receiving immune checkpoint inhibitors: a review and meta-analysis. Onco Targets Ther 23(11):955\u2013965","journal-title":"Onco Targets Ther"},{"issue":"3","key":"4455_CR36","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1080\/1120009X.2020.1819069","volume":"33","author":"P Orlandi","year":"2021","unstructured":"Orlandi P, Banchi M, Al\u00ec G, Di Desidero T, Fini E, Fontanini G, Bocci G (2021) Active metronomic vinorelbine schedules decrease plasma interleukin-2 levels in mice with Lewis lung carcinoma. J Chemother 33(3):198\u2013202","journal-title":"J Chemother"},{"issue":"10","key":"4455_CR37","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1038\/s41416-018-0076-z","volume":"118","author":"S Orecchioni","year":"2018","unstructured":"Orecchioni S, Talarico G, Labanca V, Calleri A, Mancuso P, Bertolini F (2018) Vinorelbine, cyclophosphamide and 5-FU effects on the circulating and intratumoural landscape of immune cells improve anti-PD-L1 efficacy in preclinical models of breast cancer and lymphoma. Br J Cancer 118(10):1329\u20131336","journal-title":"Br J Cancer"},{"issue":"4","key":"4455_CR38","doi-asserted-by":"publisher","first-page":"5","DOI":"10.2217\/fon-2019-0730","volume":"16","author":"A Vergnenegre","year":"2020","unstructured":"Vergnenegre A, Monnet I, Bizieux A, Bernardi M, Chiapa AM, L\u00e9na H, Choua\u00efd C, Robinet G (2020) Open-label Phase II trial to evaluate safety and efficacy of second-line metronomic oral vinorelbine-atezolizumab combination for stage-IV non-small-cell lung cancer - VinMetAtezo trial, (GFPC\u2021 04\u20132017). Future Oncol 16(4):5\u201310","journal-title":"Future Oncol"},{"issue":"5","key":"4455_CR39","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.trecan.2017.03.011","volume":"3","author":"N Andr\u00e9","year":"2017","unstructured":"Andr\u00e9 N, Tsai K, Carr\u00e9 M (2017) Pasquier E metronomic chemotherapy: direct targeting of cancer cells after all? Trends Cancer 3(5):319\u2013325","journal-title":"Trends Cancer"},{"issue":"6","key":"4455_CR40","doi-asserted-by":"publisher","first-page":"3256","DOI":"10.1158\/0008-5472.CAN-05-3885","volume":"66","author":"B Pourroy","year":"2006","unstructured":"Pourroy B, Honor\u00e9 S, Pasquier E, Bourgarel-Rey V, Kruczynski A, Briand C, Braguer D (2006) Antiangiogenic concentrations of vinflunine increase the interphase microtubule dynamics and decrease the motility of endothelial cells. Cancer Res 66(6):3256\u20133263","journal-title":"Cancer Res"},{"issue":"9","key":"4455_CR41","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.3390\/cancers13092239","volume":"13","author":"M Bondarenko","year":"2021","unstructured":"Bondarenko M, Le Grand M, Shaked Y, Raviv Z, Chapuisat G, Carr\u00e8re C, Montero MP, Rossi M, Pasquier E, Carr\u00e9 M, Andr\u00e9 N (2021) Metronomic chemotherapy modulates clonal interactions to prevent drug resistance in non-small cell lung cancer. Cancers (Basel) 13(9):2239","journal-title":"Cancers (Basel)"},{"key":"4455_CR42","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.lungcan.2021.01.005","volume":"153","author":"M Provencio","year":"2021","unstructured":"Provencio M, Majem M, Guirado M, Massuti B, de Las PR, Ortega AL, D\u00f3mine M, Mars\u00e9 R, Sala M\u00c1, Paredes A, Mor\u00e1n T, V\u00e1zquez S, Coves J, Larriba JLG, S\u00e1nchez JM, Vicente D, Farr\u00e9 N, Fornos LF, Zapata I, Franco F, Serna-Blasco R, Romero A, Isla D (2021) Lung Cancer 153:25\u201334","journal-title":"Lung Cancer"},{"key":"4455_CR43","doi-asserted-by":"publisher","first-page":"373","DOI":"10.2217\/fon.15.306","volume":"12","author":"ME Cazzaniga","year":"2016","unstructured":"Cazzaniga ME, Camerini A, Addeo R, Nol\u00e8 F, Munzone E, Collov\u00e0 E, Del Conte A, Mencoboni M, Papaldo P, Pasini F, Saracchini S, Bocci G (2016) Metronomic oral vinorelbine in advanced breast cancer and non-small-cell lung cancer: current status and future development. Future Oncol 12:373\u2013387","journal-title":"Future Oncol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-022-04455-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-022-04455-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-022-04455-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,8]],"date-time":"2022-08-08T12:05:11Z","timestamp":1659960311000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-022-04455-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,22]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["4455"],"URL":"https:\/\/doi.org\/10.1007\/s00280-022-04455-x","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,22]]},"assertion":[{"value":"25 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The other authors have no COI to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}